## Claims

1. ~~A~~ Use of a composition comprising a proteinaceous mixture, ~~said composition being obtainable~~wherein the composition is obtained from a culture supernatant in a late-exponential phase of *Lactobacillus rhamnosus* Goldin Gorbach ~~an~~ (LGG) batch- cultivation process, wherein the culture supernatant comprises molecular weight constituents above 6kDa, in the manufacture of a medicament for use in the treatment or prevention of allergic diseases.

2. ~~A composition for use in the treatment or prevention of allergic diseases~~The use according to claim 1, obtainable by a process comprising the steps of (a) subjecting LGG to cultivation in a suitable culture medium using a batch process; (b) harvesting the culture supernatant at a late exponential phase of the cultivation step, which phase is defined with reference to the second half of the time between the lag phase and the stationary phase of the LGG batch-cultivation process; (c) optionally removing low molecular weight constituents from the supernatant so as to retain molecular weight constituents above 6 kDa; (d) removing liquid contents from the culture supernatant so as to obtain the composition.

3. ~~A composition~~The use according to claim 1 or 2, wherein the late exponential phase is defined with reference to the latter quarter portion of the time between the lag phase and the stationary phase of the LGG batch-cultivation process, preferably 0.75-0.85 of the time elapsed in the exponential phase.

4. ~~A composition~~The use according to any one of the preceding claims, wherein the LGG batch cultivation is conducted in a culture medium devoid of ~~Tween 80~~a polysorbate surfactant, the medium optionally containing an oily ingredient selected from the group consisting of oleic acid, linseed oil, olive oil, rape seed oil, sunflower oil, and mixtures thereof.

5. ~~A composition~~The use according to any one of the preceding claims, wherein the LGG batch cultivation is conducted at neutral pH, preferably pH 6, at physiological temperature, preferably 37°C.

6. ~~A composition~~The use according to any one of the preceding claims, wherein the composition is in a dried form, preferably spray-dried or freeze-dried.

7. ~~A composition~~The use according to claim 6, wherein a pharmaceutically acceptable carrier material, such as maltodextrin DE29, is added to the supernatant, followed by spray- drying.

8. An infant or children's formula which is nutritionally complete with reference to the presence of lipids, carbohydrates, proteins, vitamins and minerals, further comprising ~~a composition~~the medicament according to any one of the claims 1-7.

9. ~~A composition~~The use according to any one of the claims 1-7, wherein the medicament is in the form of a dietetic product, preferably a nutritional product, or an additive for such a product, preferably a nutritional product.

10. ~~A composition~~The use according to claim 9, wherein the dietetic product further comprises one or more polyunsaturated fatty acids (PUFA's), preferably long-chain polyunsaturated fatty acids (LC-PUFA's) such as arachidonic acid (ARA) or docosahexaenoic acid (DHA).

11. ~~A composition~~The use according to claim 9 or 10, wherein the dietetic product further comprises one or more bio-active ingredients, such as proteins or polysaccharides, normally present in human breast milk.

12. ~~A composition~~The use according to any one of the claims 9-11, wherein the dietetic product further comprises one or more prebiotics, preferably selected from the group consisting of non- digestible oligosaccharides, non-digestible polysaccharides, and mixtures thereof.

13. ~~A composition~~The use according to any one of the claims 9-12, wherein the dietetic product is a prenatal, infant or children's formula or nutritional composition or supplement, a medical food, or a food for specific medical purposes.